Provigil and Tadalafil Interaction: What You Need to Know

Modafinil (brand name Provigil) is a wakefulness-promoting agent approved for narcolepsy, obstructive sleep apnea-related sleepiness, and shift work disorder. Tadalafil (brand name Cialis at doses up to 20 mg, and Adcirca at 40 mg) is a PDE5 inhibitor approved for erectile dysfunction, benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). These are different drug classes with no overlapping receptor target, but they intersect at a shared liver enzyme.

Direct answer: Modafinil is identified in its FDA prescribing information as an inducer of CYP3A4, and tadalafil is metabolized primarily through that same enzyme. In theory, this means modafinil could lower tadalafil blood levels over time and reduce its effect. No published clinical trial has measured tadalafil pharmacokinetics during concurrent modafinil use, so the actual size of that effect in this specific pairing is unverified. The combination is not listed as contraindicated by either manufacturer, but a prescriber should know both drugs are being taken together and should watch for reduced tadalafil effect rather than assume none exists.

The mechanism, stated carefully

Cytochrome P450 3A4 (CYP3A4) is the primary hepatic enzyme responsible for breaking down tadalafil. Enzyme inducers speed up this process, which lowers the drug's concentration in the blood over the course of treatment. Modafinil's FDA label describes it as capable of reducing plasma concentrations of drugs cleared through CYP3A4, and it specifically warns that hormonal contraceptives (also CYP3A4 substrates) may become less effective during modafinil therapy and for a period after stopping it (according to modafinil's prescribing information). The same enzyme dependency that makes oral contraceptives vulnerable applies, in principle, to tadalafil.

Tadalafil's own labeling for both Cialis and Adcirca identifies strong CYP3A4 inducers, such as rifampin and carbamazepine, as agents that reduce tadalafil exposure and recommends caution or dose adjustment with such drugs (Cialis prescribing information; Adcirca prescribing information). Neither label names modafinil directly, and modafinil is generally classified as a moderate rather than strong inducer, which is a meaningfully different category than rifampin or carbamazepine.

Enzyme induction is not immediate. As a general pharmacology principle, CYP3A4 upregulation from an inducing drug develops gradually, typically becoming apparent over one to two weeks of continuous dosing rather than after a single dose, because it depends on increased enzyme synthesis rather than direct enzyme blockade.

What is established, what is plausible, and what is not

evidence boundary Established (supported by FDA labeling):

• Modafinil is classified as an inducer of CYP3A4 in its own prescribing information.
• Tadalafil is cleared primarily through CYP3A4, and known strong CYP3A4 inducers reduce its blood levels enough that dose adjustment is discussed in tadalafil labeling.
• Tadalafil combined with any nitrate, including recreational nitrites, can cause a dangerous drop in blood pressure. This rule is independent of modafinil and does not change with or without it.
• Tadalafil is not recommended in patients with severe hepatic impairment, and modafinil dosing should be reduced in severe hepatic impairment per its label.

Pharmacologically plausible but not directly measured:

• That modafinil's induction of CYP3A4 reduces tadalafil blood levels enough to matter clinically in some patients, based on the shared pathway described above.
• That patients on lower tadalafil doses (2.5 to 5 mg daily for ED or BPH), who have less margin above the minimum effective concentration, would notice this effect sooner than patients on higher as-needed doses.
• That armodafinil (Nuvigil), modafinil's single-enantiomer relative, produces a smaller but qualitatively similar CYP3A4 induction effect. This has not been confirmed against tadalafil specifically.

Not established:

• The magnitude of any tadalafil AUC reduction caused by modafinil specifically. No dedicated pharmacokinetic study of this drug pair has been published. Any specific percentage figure for this combination should be treated as an estimate requiring verification against primary literature, not a confirmed value.
• Whether the interaction produces a clinically meaningful hemodynamic (blood pressure or heart rate) effect beyond the ordinary, separate pharmacologic profiles of each drug.
• Whether older age, renal impairment, or hepatic impairment predictably increases or decreases the size of the interaction in this specific pair.

Evidence-status interaction assessment

Who is most likely to notice a problem

Two groups deserve closer attention, though neither is proven to experience a defined percentage change in drug level.

Men on tadalafil 2.5 to 5 mg daily for ED or BPH. These lower daily doses have less pharmacologic margin. If a patient who was previously stable on a daily low dose reports a gradual decline in effect after starting modafinil, CYP3A4 induction is a reasonable pharmacokinetic explanation to consider before assuming disease progression or unrelated new pathology, though it should not be assumed to be the only explanation.

Patients on tadalafil 40 mg (Adcirca) for pulmonary arterial hypertension. PAH is a hemodynamically fragile condition, and the Adcirca label already advises against combining it with strong CYP3A4 inducers because reduced exposure could allow pulmonary vascular resistance to worsen. Modafinil is a moderate, not strong, inducer, but any patient on Adcirca who is being considered for modafinil should have that decision made jointly with the prescribing cardiologist or pulmonologist rather than assumed safe by default.

Practical monitoring approach

There is no published protocol specific to this drug pair. The following is a reasonable, conservative approach based on general enzyme-induction pharmacology and each drug's own labeling, not a validated clinical guideline.

Before starting modafinil in a patient stable on tadalafil, it is reasonable to document the current tadalafil dose and indication, baseline blood pressure and heart rate, any other CYP3A4-active drugs already in the regimen, and cardiovascular history.

After starting modafinil, a follow-up check around two to four weeks (the general window in which enzyme induction is expected to reach a new steady state) is a reasonable point to ask about tadalafil effect and recheck blood pressure. If effect has declined, the physician can decide whether a dose adjustment within FDA-approved limits, a change in modafinil dose, or a switch in wakefulness agent is appropriate. Self-adjusting either drug's dose without medical guidance is not appropriate, and increasing tadalafil above its FDA-approved ceiling (20 mg per 24 hours as-needed, or 5 mg per day for daily use) is off-label and should not be done reflexively.

Nitrates: the rule that does not change

Tadalafil combined with any nitrate medication, or with recreational nitrites ("poppers"), can cause a severe and dangerous drop in blood pressure. This is true whether or not the patient also takes modafinil. Anyone taking tadalafil should disclose that fact before receiving nitroglycerin or any nitrate-based treatment in an emergency setting.

Modafinil's broader interaction profile

Because modafinil affects two different metabolic pathways in opposite directions, a full medication review matters beyond tadalafil alone.

• CYP3A4 substrates that may become less effective: hormonal contraceptives (the Provigil label specifically recommends alternative or additional contraception during modafinil use and for a period after stopping), and other drugs cleared mainly through CYP3A4.
• CYP2C19 substrates that may accumulate: modafinil inhibits CYP2C19, so drugs like omeprazole, phenytoin, and diazepam may reach higher-than-expected levels when modafinil is added. This is the opposite direction of the tadalafil interaction and is a reason a pharmacist should review the entire drug list rather than only the one interaction in question.

Special populations, stated with appropriate caution

Older adults. Both drugs have their own age-related dosing considerations independent of each other: tadalafil is generally not recommended above 5 mg per day in men over 65 without confirming renal and hepatic function support a higher dose, per its label. Whether modafinil's induction effect is smaller or larger in older patients specifically has not been established for this drug pair.

Severe hepatic impairment. Modafinil dosing should be reduced according to its label in severe hepatic impairment, and tadalafil is not recommended in this population at all. Combining both drugs in a patient with Child-Pugh C liver disease should not happen outside specialist supervision.

Severe renal impairment. Tadalafil already accumulates more in patients with a creatinine clearance below 30 mL/min, per its label. Whether concurrent modafinil meaningfully changes that picture has not been studied, and this population should be managed with direct renal and urology input rather than by assumption.

What the evidence base actually consists of

As of this writing, no randomized or crossover pharmacokinetic study of modafinil combined with tadalafil has been published. The current basis for this interaction is indirect: each drug's independent FDA labeling describes the CYP3A4 relationship, and general enzyme-induction pharmacology supports the theoretical direction of the effect. That is a reasonable basis for caution and monitoring. It is not a basis for citing a specific percentage change in tadalafil blood levels as a confirmed fact. Any source presenting a precise number for this specific combination should be checked against the primary pharmacokinetic literature before it is repeated to a patient or used to guide a dose decision. General background on how clinicians reason through drug-drug interactions, including why moderate-inducer effects are sometimes under-recognized because they develop slowly, is available from the National Library of Medicine's StatPearls resource (NCBI Bookshelf: Drug Interactions).

Professional urology guidance generally supports individualizing ED treatment based on efficacy and tolerability within approved dosing limits rather than fixed ceilings below the maximum approved dose (American Urological Association), which is relevant background for how a prescriber might respond to reported loss of effect, though it does not specifically address the modafinil interaction.

When to seek urgent care

Chest pain, fainting, a sudden and severe drop in blood pressure, or an erection lasting more than four hours (priapism) after taking tadalafil are reasons for urgent medical evaluation regardless of whether modafinil is also being taken. Patients on tadalafil for PAH should not stop the drug abruptly and should contact their treating specialist if breathing symptoms worsen.